Diamedica Therapeutics (DMAC)
NASDAQ:DMAC
Want to see DMAC full AI Analyst Report?
Total Valuation
Diamedica Therapeutics has a market cap or net worth of $318.45M. The enterprise value is $313.79M.
Market Cap$318.45M
Enterprise Value$313.79M
Share Statistics
Diamedica Therapeutics has 53,883,347 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53,883,347
Owned by Insiders43.45%
Owned by Institutions―
Financial Efficiency
Diamedica Therapeutics’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -61.04%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-61.04%
Return on Capital Employed (ROCE)-0.61
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count27
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Diamedica Therapeutics is ―. Diamedica Therapeutics’s PEG ratio is -0.68.
PE Ratio―
PS Ratio0.00
PB Ratio6.66
Price to Fair Value6.66
Price to FCF-12.85
Price to Operating Cash Flow-10.95
PEG Ratio-0.68
Income Statement
In the last 12 months, Diamedica Therapeutics had revenue of 0.00 and earned -32.77M in profits. Earnings per share was -0.70.
Revenue0.00
Gross Profit0.00
Operating Income-34.40M
Pretax Income-32.74M
Net Income-32.77M
EBITDA-34.35M
Earnings Per Share (EPS)-0.70
Cash Flow
In the last 12 months, operating cash flow was -31.05M and capital expenditures -36.19K, giving a free cash flow of -31.09M billion.
Operating Cash Flow-31.05M
Free Cash Flow-31.09M
Free Cash Flow per Share-0.58
Dividends & Yields
Diamedica Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change52.29%
50-Day Moving Average6.43
200-Day Moving Average7.16
Relative Strength Index (RSI)52.45
Average Volume (3m)158.82K
Important Dates
Diamedica Therapeutics upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Diamedica Therapeutics as a current ratio of 11.81, with Debt / Equity ratio of 0.45%
Current Ratio11.81
Quick Ratio11.81
Debt to Market Cap0.00
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Diamedica Therapeutics has paid 28.00K in taxes.
Income Tax28.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Diamedica Therapeutics EV to EBITDA ratio is -10.44, with an EV/FCF ratio of -12.32.
EV to Sales0.00
EV to EBITDA-10.44
EV to Free Cash Flow-12.32
EV to Operating Cash Flow-12.34
Balance Sheet
Diamedica Therapeutics has $51.33M in cash and marketable securities with $212.00K in debt, giving a net cash position of $51.12M billion.
Cash & Marketable Securities$51.33M
Total Debt$212.00K
Net Cash$51.12M
Net Cash Per Share$0.95
Tangible Book Value Per Share$1.19
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Diamedica Therapeutics is $13.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.00
Price Target Upside89.78% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast-9.22%